Tracking Labeled Red Blood Cells After Transfusion
This study tests a special way to label your own red blood cells so doctors can track how long they survive in your body. It helps improve how we measure blood cell recovery after transfusion.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must be in overall good health (based on your medical history and a physical exam).
- Your height and weight must meet requirements: men taller than 5'1" and heavier than 130 lbs; women taller than 5'5" and heavier than 150 lbs.
- Your blood counts and other lab tests must be normal (or only slightly off and not a concern to the doctor).
- You must not be pregnant, nursing, or planning to get pregnant during the study, and you must use an effective birth control method (including a barrier method) if you are of childbearing potential.
- You cannot have a known red blood cell disorder, be taking medicines that affect red blood cells, have had a blood transfusion in the past year, or have been in another clinical trial in the last 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to treat donated red blood cells (called INTERCEPT) to see how long they survive in the body and how well they recover. It may help make blood transfusions safer for people who need them.
This study uses a harmless vitamin (biotin) to label your red blood cells and track how long they survive. It aims to understand how different blood disorders affect red blood cell lifespan, which may help improve treatments.
This study tests whether red blood cells treated with a special process (INTERCEPT) are safe and work well when given to people who have or don't have antibodies to these treated cells. It aims to understand if the treated cells can be used for transfusions in patients who have developed antibodies from previous transfusions.
This study compares two different strategies for when to give red blood cell transfusions to people receiving intensive chemotherapy or stem cell transplant for high-grade myeloid neoplasms, AML or B-ALL. The goal is to see which approach better improves quality of life and daily function.
This study collects blood cells (apheresis) from healthy volunteers to help develop new medicines. It checks your overall health to make sure you're a safe donor.
This trial tests whether using a measure of oxygen in your body can guide doctors on when to give you a blood transfusion. It may help avoid unnecessary transfusions while ensuring you get enough oxygen.
Hear when a new Healthy Volunteer Red Blood Cell Labeling Study; Not Disease Focused trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.